Dr. Herbst, Professor of Medicine, Medical Oncology, Professor of Pharmacology, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Associate Cancer Center Director for Translational Research, Yale Cancer Center, tell us about the PIONeeR study presented at the 2020 ESMO Virtual Congress and what it means for precision medicine and PD-L1 status in the management of non-small cell lung cancer (NSCLC) patients